Q32 Bio spent a year shrinking itself into a single-asset alopecia company, then used an open-label mid-stage readout to refill the balance sheet at a price the market no longer supports. In mid-July management reported clinically meaningful hair-regrowth activity for bempikibart in severe alopecia areata and, one session later, priced a large follow-on. The September close sits well below that offering print. The investment debate is no longer whether the company survives to the next dataset. It is whether an unblinded thirty-three patient study can support a first-line biologic claim against already-approved oral JAK inhibitors, and whether the current enterprise value still treats that claim as a cheap option.
The open-label Part B cohort treated patients with severe or very severe disease for thirty-six weeks. Mean Severity of Alopecia Tool score fell by more than a third in the modified intent-to-treat set. Two in five of those patients reached eighty percent scalp coverage, and the intent-to-treat rate was lower once every enrolled patient was counted. Roughly one third of the cohort had already failed an oral JAK inhibitor, which is the commercial claim the equity is now pricing. Safety looked consistent with earlier work and did not produce a new signal. That package was enough to raise roughly $188 million of net proceeds after quarter-end, on top of cash that had already more than doubled during the first half.
What remains open is durability off drug, the Food and Drug Administration's view of an open-label package, and how fast spending rises once a registration-directed program starts. Half-year operating cash use was still modest because the complement program had been sold and the late-stage trial had not begun. That burn rate does not survive a multi-center registrational program. The next year resolves whether regulators accept the current design path and whether later off-drug and extension data still support a durability story oral JAK inhibitors have not owned.